A Phase III Study of AL3818 (Anlotinib) HydrochlorideMonotherapy in Subjects with Metastatic or AdvancedAlveolar Soft Part Sarcoma, Leiomyosarcoma and SynovialSarcoma

Protocol: 
AAAS0001
Phase: 
III

A Phase III Study of AL3818 (Anlotinib) HydrochlorideMonotherapy in Subjects with Metastatic or AdvancedAlveolar Soft Part Sarcoma, Leiomyosarcoma and SynovialSarcoma

The researchers hope to study the effectiveness of an investigational drug
called AL3818 in people who have metastatic (meaning their disease has
spread) or advanced sarcoma, specifically alveolar soft part sarcoma (ASPS),
leiomyosarcoma (LMS) and synovial sarcoma (SS). For patients with ASPS, the
main purpose of the study is to learn the percentage of patients that
respond to treatment with AL3818. For patients with LMS and SS, the main
purpose of the study is to understand whether AL3818 delays the time until
the cancer worsens when compared to another drug called dacarbazine
(standard treatment). Other purposes of the study are to learn how long
people respond to AL3818, if AL3818 extends overall survival and evaluate
the safety of AL3818.

Are you Eligible? (Inclusion Criteria)

Are you 18 years of age or older?
Do you have a life expectancy of at least 3 months?
Have you been diagnosed with metastatic (meaning their disease has spread)
or locally advanced sarcoma, specifically alveolar soft part sarcoma (ASPS),
leiomyosarcoma (LMS) or synovial sarcoma (SS)?
Did your disease get worse after the last time you received standard
therapy?

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States